MedTrace Logo

Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients

NCT00257257 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2009-04-20

No results posted yet for this study

Summary

Primary: Effect on HbA1c over 6 months in drug-naive patients with type 2 diabetes

Secondary: Effect on glucose, insulin, C-peptide, insulin resistance, body weight, HDL-cholesterol, triglycerides, blood pressure - Safety, tolerability

Conditions

Interventions

DRUG

Rimonabant (SR141716)

Sponsors & Collaborators

Principal Investigators

  • ICD CSD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • United States
  • Argentina
  • Chile
  • Germany
  • Hungary
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257257 on ClinicalTrials.gov